Navigation Links
Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
Date:3/7/2012

SAN DIEGO, March  7, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the following two investor conferences in March:

  • 24th Annual Roth Conference in Dana Point on March 14, 2012 at 12:30 p.m. ET/9:30 a.m. PT. Kurt Gustafson, Chief Financial Officer of Halozyme Therapeutics, will provide a corporate overview.
  • Barclays Capital 2012 Global Healthcare Conference in Miami on March 14, 2012 at 4:15 p.m. ET/1:15 p.m. PT. Gregory I. Frost, Ph.D., President and Chief Executive Officer of Halozyme Therapeutics, will provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentations will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and recordings will be made available for 90 days following the events. To access the live webcasts, please log on to Halozyme's website approximately fifteen minutes prior to the presentations to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headqua
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
2. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
4. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
5. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
6. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
7. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
8. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
9. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
10. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
11. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 23, 2014 ViaDerma, Inc ... company devoted to bringing new products to market, ... , ViaDerma has developed an innovative, patent-pending dual ... mass transfer of pharmaceutical active ingredients to penetrate ... immediate localized therapy. The transdermal delivery method also ...
(Date:10/25/2014)... According to new market research report "Data Center ... Telecom), by Design Types (Electrical, Mechanical), and by ... Tier 4) - Global Forecast to 2019", published ... Construction Market into various segments with an in-depth ... also identifies the factors driving this market, various ...
(Date:10/25/2014)... 24, 2014 The Workgroup ... leading nonprofit authority on the use of health ... announces its appointment of four new co-chairs to ... leaders include:, ,     Peter Dumont, Senior ... Pupo, Specialist Leader, Deloitte Consulting LLP , ...
(Date:10/25/2014)... Today, Nerium International, a leader in ... its “Reflect Your Youth” contest, an effort launched to ... difference in their skin since using Nerium’s product line, ... life as a result of their newfound confidence. , ... by Nerium International to inspire conversations focused on the ...
Breaking Biology Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2
... - MacoPharma increased its forecast for P-Capt(R) filters sale in 2008;, - Use of affinity prion adsorbent for ... in excess of $25 M over the next 5 years ... - $4 M in 2008;,- 10th product approved by the FDA and or the EMEA, contributing ... growth., MONTREAL, ...
... Cholesterol Test Can Help Identify Patients At Risk of Heart ... ... Atherotech, Inc., a,cardio-diagnostic company, today announced that the largest private,insurers in ... (FEHB) Program now cover the VAP (Vertical Auto Profile),Test, the most ...
... Software Platform Further Solidifies Netsmart as Leader in Behavioral Healthcare ... ... Florida, GREAT RIVER, N.Y., Feb. 6 Netsmart Technologies, Inc.,a ... organizations, today announced it has signed a contract to,provide comprehensive licensed ...
Cached Biology Technology:ProMetic provides business update - Over $35 million worth of business secured in January 2ProMetic provides business update - Over $35 million worth of business secured in January 3ProMetic provides business update - Over $35 million worth of business secured in January 4VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3
(Date:10/27/2014)... in German . ... interior via electrical signals, they communicate with each other ... messenger substances, the neurotransmitters, are stored in vesicles at ... these vesicles fuse with the cell membrane and release ... lost, synapses always have some readily releasable vesicles on ...
(Date:10/27/2014)... — Recent breakthroughs may pave the way for ... parasitic helminths. These flatworms, including tapeworms that cause ... flukes (schistosomes), infect more than 300 million people ... lost due to chronic illness and death each ... of microbiology, immunology, and tropical medicine, and scientific ...
(Date:10/27/2014)... 27, 2014—New results from a safety and immunogenicity ... efficacy, indicate that a live attenuated enterotoxigenic ... combination with a novel adjuvant, provided significant protection ... for this vaccine/adjuvant combination, which was 58.5 percent ... using a highly rigorous ETEC human challenge model. ...
Breaking Biology News(10 mins):Synapses always on the starting blocks 2Synapses always on the starting blocks 3GW researcher adapting breakthrough technologies to combat parasitic worm infections 2Clinical results indicate vaccine candidate highly efficacious against bacterial diarrhea 2
... institutions led by the Georgia Institute of Technology has ... Science Foundation and the National Aeronautics and Space Administration ... understanding of how life started on Earth. Researchers will ... the spontaneous formation of functional polymers -- such as ...
... , The Virginia Tech Colleges of Engineering, Science, and ... million, five-year grant from the National Science Foundation (NSF) ... future researchers to solve emerging challenges at the intersection ... The MultiSTEPS (Multi-Scale Transport in Environmental and Physiological Systems) ...
... The 2010 Annual Meeting & OTO EXPO of the ... (AAO-HNSF), the largest meeting of ear, nose, and throat doctors ... The official abstract supplement for the annual meeting is now ... of Otolaryngology Head and Neck Surgery . (See ...
Cached Biology News:Georgia Tech awarded a $20M Center for Chemical Innovation from NSF and NASA 2Georgia Tech awarded a $20M Center for Chemical Innovation from NSF and NASA 3NSF funds Virginia Tech program to train researchers at intersection of engineering, biology 2NSF funds Virginia Tech program to train researchers at intersection of engineering, biology 3Otolaryngology -- Head and Neck Surgery Annual Meeting supplement now available 2
... DNase is a preparation of deoxyribonuclease ... DNA to produce 3-hydroxyl oligonucleotides. This ... applications where maintaining the integrity of ... qualified for use with the Core ...
... Type Liquid. In 100 mM KCl, ... EDTA, 20% glycerol, pH 7.9. AVOID FREEZE/THAW CYCLES. ... monomeric protein of 765 amino acids encoded by ... both positive and negative supercoiled DNAs without the ...
Request Info...
... III digests duplex DNA in a 3'-> ... or nick, producing stretches of single-stranded DNA. ... Exonuclease III proceeds at a uniform rate ... rate of exonucleolytic excision of deoxyribonucleotides by ...
Biology Products: